ID   MA1B1_HUMAN             Reviewed;         699 AA.
AC   Q9UKM7; Q5VSG3; Q9BRS9; Q9Y5K7;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase;
DE            EC=3.2.1.113 {ECO:0000269|PubMed:10409699, ECO:0000269|PubMed:12090241, ECO:0000269|PubMed:15713668};
DE   AltName: Full=ER alpha-1,2-mannosidase;
DE   AltName: Full=ER mannosidase 1;
DE            Short=ERMan1;
DE   AltName: Full=Man9GlcNAc2-specific-processing alpha-mannosidase;
DE   AltName: Full=Mannosidase alpha class 1B member 1;
GN   Name=MAN1B1; ORFNames=UNQ747/PRO1477;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], BIOPHYSICOCHEMICAL PROPERTIES, TISSUE
RP   SPECIFICITY, AND VARIANT SER-59.
RC   TISSUE=Fetal brain, Liver, Placenta, and Testis;
RX   PubMed=10521544; DOI=10.1093/glycob/9.10.1073;
RA   Tremblay L.O., Herscovics A.;
RT   "Cloning and expression of a specific human alpha1,2-mannosidase that
RT   trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan
RT   biosynthesis.";
RL   Glycobiology 9:1073-1078(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 37-699, TISSUE SPECIFICITY, ENZYME
RP   ACTIVITY, ENZYME REGULATION, SUBCELLULAR LOCATION, AND VARIANT SER-59.
RX   PubMed=10409699; DOI=10.1074/jbc.274.30.21375;
RA   Gonzalez D.S., Karaveg K., Vandersall-Nairn A.S., Lal A.,
RA   Moremen K.W.;
RT   "Identification, expression, and characterization of a cDNA encoding
RT   human endoplasmic reticulum mannosidase I, the enzyme that catalyzes
RT   the first mannose trimming step in mammalian Asn-linked
RT   oligosaccharide biosynthesis.";
RL   J. Biol. Chem. 274:21375-21386(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-59.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-59.
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.
RX   PubMed=12090241;
RA   Herscovics A., Romero P.A., Tremblay L.O.;
RT   "The specificity of the yeast and human class I ER alpha 1,2-
RT   mannosidases involved in ER quality control is not as strict
RT   previously reported.";
RL   Glycobiology 12:14G-15G(2002).
RN   [7]
RP   FUNCTION.
RX   PubMed=18003979; DOI=10.1091/mbc.E07-05-0505;
RA   Avezov E., Frenkel Z., Ehrlich M., Herscovics A., Lederkremer G.Z.;
RT   "Endoplasmic reticulum (ER) mannosidase I is compartmentalized and
RT   required for N-glycan trimming to Man5-6GlcNAc2 in glycoprotein ER-
RT   associated degradation.";
RL   Mol. Biol. Cell 19:216-225(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 243-699, AND DISULFIDE BOND.
RX   PubMed=10995765; DOI=10.1074/jbc.M006927200;
RA   Vallee F., Karaveg K., Herscovics A., Moremen K.W., Howell P.L.;
RT   "Structural basis for catalysis and inhibition of N-glycan processing
RT   class I alpha 1,2-mannosidases.";
RL   J. Biol. Chem. 275:41287-41298(2000).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.41 ANGSTROMS) OF 172-699 IN COMPLEX WITH A
RP   THIO-DISACCHARIDE SUBSTRATE ANALOG, ENZYME ACTIVITY, AND MUTAGENESIS
RP   OF GLU-330; ASP-463; HIS-524 AND GLU-599.
RX   PubMed=15713668; DOI=10.1074/jbc.M500119200;
RA   Karaveg K., Siriwardena A., Tempel W., Liu Z.J., Glushka J.,
RA   Wang B.C., Moremen K.W.;
RT   "Mechanism of class 1 (glycosylhydrolase family 47) {alpha}-
RT   mannosidases involved in N-glycan processing and endoplasmic reticulum
RT   quality control.";
RL   J. Biol. Chem. 280:16197-16207(2005).
RN   [11]
RP   VARIANTS MRT15 CYS-334 AND LYS-397, AND CHARACTERIZATION OF VARIANTS
RP   MRT15 CYS-334 AND LYS-397.
RX   PubMed=21763484; DOI=10.1016/j.ajhg.2011.06.006;
RA   Rafiq M.A., Kuss A.W., Puettmann L., Noor A., Ramiah A., Ali G.,
RA   Hu H., Kerio N.A., Xiang Y., Garshasbi M., Khan M.A., Ishak G.E.,
RA   Weksberg R., Ullmann R., Tzschach A., Kahrizi K., Mahmood K.,
RA   Naeem F., Ayub M., Moremen K.W., Vincent J.B., Ropers H.H., Ansar M.,
RA   Najmabadi H.;
RT   "Mutations in the alpha 1,2-mannosidase gene, MAN1B1, cause autosomal-
RT   recessive intellectual disability.";
RL   Am. J. Hum. Genet. 89:176-182(2011).
CC   -!- FUNCTION: Involved in glycoprotein quality control targeting of
CC       misfolded glycoproteins for degradation. It primarily trims a
CC       single alpha-1,2-linked mannose residue from Man(9)GlcNAc(2) to
CC       produce Man(8)GlcNAc(2), but at high enzyme concentrations, as
CC       found in the ER quality control compartment (ERQC), it further
CC       trims the carbohydrates to Man(5-6)GlcNAc(2).
CC       {ECO:0000269|PubMed:12090241, ECO:0000269|PubMed:18003979}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of the terminal (1->2)-linked
CC       alpha-D-mannose residues in the oligo-mannose oligosaccharide
CC       Man(9)(GlcNAc)(2). {ECO:0000269|PubMed:10409699,
CC       ECO:0000269|PubMed:12090241, ECO:0000269|PubMed:15713668}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000250|UniProtKB:P45700};
CC   -!- ENZYME REGULATION: Inhibited by both 1-deoxymannojirimycin (dMNJ)
CC       and kifunensine. {ECO:0000269|PubMed:10409699}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.4 mM for Man9GlcNAc2 {ECO:0000269|PubMed:10521544};
CC       pH dependence:
CC         Optimum pH is between 6.5 and 6.9.
CC         {ECO:0000269|PubMed:10521544};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000250|UniProtKB:P32906}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10409699}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:10409699}.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:10409699, ECO:0000269|PubMed:10521544}.
CC   -!- DISEASE: Mental retardation, autosomal recessive 15 (MRT15)
CC       [MIM:614202]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. {ECO:0000269|PubMed:21763484}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 47 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-37 is the initiator.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF148509; AAF03215.1; -; mRNA.
DR   EMBL; AF145732; AAD45504.1; -; mRNA.
DR   EMBL; AY358465; AAQ88830.1; -; mRNA.
DR   EMBL; AL929554; CAH72887.1; -; Genomic_DNA.
DR   EMBL; AL807752; CAH72887.1; JOINED; Genomic_DNA.
DR   EMBL; AL807752; CAI12781.1; -; Genomic_DNA.
DR   EMBL; AL929554; CAI12781.1; JOINED; Genomic_DNA.
DR   EMBL; BC002953; AAH02953.1; -; mRNA.
DR   EMBL; BC006079; AAH06079.1; -; mRNA.
DR   CCDS; CCDS7029.1; -.
DR   RefSeq; NP_057303.2; NM_016219.4.
DR   UniGene; Hs.279881; -.
DR   PDB; 1FMI; X-ray; 1.90 A; A=243-697.
DR   PDB; 1FO2; X-ray; 2.38 A; A=243-699.
DR   PDB; 1FO3; X-ray; 1.75 A; A=243-699.
DR   PDB; 1X9D; X-ray; 1.41 A; A=172-699.
DR   PDBsum; 1FMI; -.
DR   PDBsum; 1FO2; -.
DR   PDBsum; 1FO3; -.
DR   PDBsum; 1X9D; -.
DR   ProteinModelPortal; Q9UKM7; -.
DR   SMR; Q9UKM7; -.
DR   BioGrid; 116414; 6.
DR   IntAct; Q9UKM7; 3.
DR   MINT; MINT-6610355; -.
DR   STRING; 9606.ENSP00000360645; -.
DR   BindingDB; Q9UKM7; -.
DR   ChEMBL; CHEMBL2308; -.
DR   DrugBank; DB03206; Duvoglustat.
DR   DrugBank; DB02742; Kifunensine.
DR   DrugBank; DB02422; Methyl-2-S-(Alpha-D-Mannopyranosyl)-2-Thio-Alpha-D-Mannopyranoside.
DR   CAZy; GH47; Glycoside Hydrolase Family 47.
DR   iPTMnet; Q9UKM7; -.
DR   PhosphoSitePlus; Q9UKM7; -.
DR   SwissPalm; Q9UKM7; -.
DR   BioMuta; MAN1B1; -.
DR   DMDM; 93195043; -.
DR   EPD; Q9UKM7; -.
DR   MaxQB; Q9UKM7; -.
DR   PaxDb; Q9UKM7; -.
DR   PeptideAtlas; Q9UKM7; -.
DR   PRIDE; Q9UKM7; -.
DR   DNASU; 11253; -.
DR   Ensembl; ENST00000371589; ENSP00000360645; ENSG00000177239.
DR   GeneID; 11253; -.
DR   KEGG; hsa:11253; -.
DR   UCSC; uc004cld.3; human.
DR   CTD; 11253; -.
DR   DisGeNET; 11253; -.
DR   GeneCards; MAN1B1; -.
DR   H-InvDB; HIX0035043; -.
DR   HGNC; HGNC:6823; MAN1B1.
DR   HPA; HPA051516; -.
DR   MalaCards; MAN1B1; -.
DR   MIM; 604346; gene.
DR   MIM; 614202; phenotype.
DR   neXtProt; NX_Q9UKM7; -.
DR   OpenTargets; ENSG00000177239; -.
DR   Orphanet; 88616; Autosomal recessive non-syndromic intellectual disability.
DR   Orphanet; 397941; MAN1B1-CDG.
DR   PharmGKB; PA30572; -.
DR   eggNOG; KOG2431; Eukaryota.
DR   eggNOG; ENOG410XP04; LUCA.
DR   GeneTree; ENSGT00390000016529; -.
DR   HOGENOM; HOG000181987; -.
DR   HOVERGEN; HBG052389; -.
DR   InParanoid; Q9UKM7; -.
DR   KO; K01230; -.
DR   OMA; ACEGRRS; -.
DR   OrthoDB; EOG091G0342; -.
DR   PhylomeDB; Q9UKM7; -.
DR   TreeFam; TF354274; -.
DR   BRENDA; 3.2.1.113; 2681.
DR   Reactome; R-HSA-901032; ER Quality Control Compartment (ERQC).
DR   UniPathway; UPA00378; -.
DR   ChiTaRS; MAN1B1; human.
DR   EvolutionaryTrace; Q9UKM7; -.
DR   GeneWiki; MAN1B1; -.
DR   GenomeRNAi; 11253; -.
DR   PRO; PR:Q9UKM7; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000177239; -.
DR   CleanEx; HS_MAN1B1; -.
DR   ExpressionAtlas; Q9UKM7; baseline and differential.
DR   Genevisible; Q9UKM7; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044322; C:endoplasmic reticulum quality control compartment; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000139; C:Golgi membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004559; F:alpha-mannosidase activity; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; TAS:UniProtKB.
DR   GO; GO:0004571; F:mannosyl-oligosaccharide 1,2-alpha-mannosidase activity; IDA:UniProtKB.
DR   GO; GO:1904380; P:endoplasmic reticulum mannose trimming; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1904382; P:mannose trimming involved in glycoprotein ERAD pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006491; P:N-glycan processing; IBA:GO_Central.
DR   GO; GO:0009311; P:oligosaccharide metabolic process; TAS:ProtInc.
DR   GO; GO:0036508; P:protein alpha-1,2-demannosylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006486; P:protein glycosylation; IEA:UniProtKB-UniPathway.
DR   GO; GO:0036511; P:trimming of first mannose on A branch; TAS:Reactome.
DR   GO; GO:0036512; P:trimming of second mannose on A branch; TAS:Reactome.
DR   GO; GO:0036509; P:trimming of terminal mannose on B branch; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0036510; P:trimming of terminal mannose on C branch; TAS:Reactome.
DR   GO; GO:0030433; P:ubiquitin-dependent ERAD pathway; IMP:UniProtKB.
DR   InterPro; IPR001382; Glyco_hydro_47.
DR   Pfam; PF01532; Glyco_hydro_47; 1.
DR   PRINTS; PR00747; GLYHDRLASE47.
DR   SUPFAM; SSF48225; SSF48225; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Disease mutation;
KW   Disulfide bond; Endoplasmic reticulum; Glycosidase; Hydrolase;
KW   Membrane; Mental retardation; Metal-binding; Polymorphism;
KW   Reference proteome; Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN         1    699       Endoplasmic reticulum mannosyl-
FT                                oligosaccharide 1,2-alpha-mannosidase.
FT                                /FTId=PRO_0000210314.
FT   TOPO_DOM      1     84       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     85    105       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM    106    699       Lumenal. {ECO:0000255}.
FT   COMPBIAS     39     45       Poly-Pro.
FT   ACT_SITE    330    330       Proton donor. {ECO:0000305}.
FT   ACT_SITE    463    463       {ECO:0000305}.
FT   ACT_SITE    570    570       Proton donor.
FT                                {ECO:0000250|UniProtKB:P31723}.
FT   ACT_SITE    599    599       {ECO:0000305}.
FT   METAL       688    688       Calcium. {ECO:0000250|UniProtKB:P32906}.
FT   DISULFID    527    556       {ECO:0000269|PubMed:10995765}.
FT   VARIANT      59     59       N -> S (in dbSNP:rs968733).
FT                                {ECO:0000269|PubMed:10409699,
FT                                ECO:0000269|PubMed:10521544,
FT                                ECO:0000269|PubMed:12975309,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_055841.
FT   VARIANT     334    334       R -> C (in MRT15; results in about 1300-
FT                                fold decrease in activity;
FT                                dbSNP:rs387906886).
FT                                {ECO:0000269|PubMed:21763484}.
FT                                /FTId=VAR_066592.
FT   VARIANT     397    397       E -> K (in MRT15; disrupts stable protein
FT                                expression; dbSNP:rs387906885).
FT                                {ECO:0000269|PubMed:21763484}.
FT                                /FTId=VAR_066593.
FT   MUTAGEN     330    330       E->Q: About 44-fold reduction in K(cat),
FT                                slight reduction in K(m), about 100-fold
FT                                increase in binding affinity for
FT                                Man(9)GlcnAc(2) but no change in binding
FT                                affinity for the inhibitor, dMNJ. Even
FT                                further greater reduction in K(cat) and
FT                                increase in K(m); when associated with Q-
FT                                599. {ECO:0000269|PubMed:15713668}.
FT   MUTAGEN     463    463       D->N: Some reduction in K(cat) but no
FT                                change in K(m), abolishes almost all
FT                                binding to Man(9)GlcnAc(2) but reduced
FT                                binding to the inhibitor dMNJ by about
FT                                73-fold. Further reduction in K(m) but
FT                                slight increase in K(m); when associated
FT                                with Q-599.
FT                                {ECO:0000269|PubMed:15713668}.
FT   MUTAGEN     524    524       H->A: About 4-fold reduction in K(cat).
FT                                {ECO:0000269|PubMed:15713668}.
FT   MUTAGEN     599    599       E->Q: Very significant reduction in
FT                                K(cat), 4-fold weaker binding affinity
FT                                for Man(9)GlcnAc(2) but about 1000-fold
FT                                reduction in binding affinity for the
FT                                inhibitor, dMNJ. Significant reductions
FT                                in K(cat) and slight increase in K(m);
FT                                when associated with E-330 or N-463.
FT                                {ECO:0000269|PubMed:15713668}.
FT   CONFLICT    204    204       T -> A (in Ref. 2; AAD45504).
FT                                {ECO:0000305}.
FT   CONFLICT    223    223       S -> P (in Ref. 2; AAD45504).
FT                                {ECO:0000305}.
FT   STRAND      244    246       {ECO:0000244|PDB:1FO3}.
FT   HELIX       248    267       {ECO:0000244|PDB:1X9D}.
FT   STRAND      271    275       {ECO:0000244|PDB:1X9D}.
FT   TURN        276    279       {ECO:0000244|PDB:1X9D}.
FT   STRAND      280    282       {ECO:0000244|PDB:1X9D}.
FT   STRAND      284    287       {ECO:0000244|PDB:1X9D}.
FT   HELIX       289    300       {ECO:0000244|PDB:1X9D}.
FT   HELIX       304    317       {ECO:0000244|PDB:1X9D}.
FT   STRAND      325    327       {ECO:0000244|PDB:1X9D}.
FT   HELIX       328    346       {ECO:0000244|PDB:1X9D}.
FT   HELIX       349    362       {ECO:0000244|PDB:1X9D}.
FT   HELIX       363    366       {ECO:0000244|PDB:1X9D}.
FT   STRAND      368    370       {ECO:0000244|PDB:1FO3}.
FT   STRAND      375    378       {ECO:0000244|PDB:1X9D}.
FT   TURN        379    381       {ECO:0000244|PDB:1X9D}.
FT   STRAND      391    394       {ECO:0000244|PDB:1X9D}.
FT   HELIX       395    399       {ECO:0000244|PDB:1X9D}.
FT   HELIX       402    412       {ECO:0000244|PDB:1X9D}.
FT   HELIX       416    429       {ECO:0000244|PDB:1X9D}.
FT   STRAND      441    444       {ECO:0000244|PDB:1X9D}.
FT   TURN        445    447       {ECO:0000244|PDB:1X9D}.
FT   STRAND      450    452       {ECO:0000244|PDB:1X9D}.
FT   TURN        460    462       {ECO:0000244|PDB:1X9D}.
FT   HELIX       463    475       {ECO:0000244|PDB:1X9D}.
FT   HELIX       481    497       {ECO:0000244|PDB:1X9D}.
FT   STRAND      499    501       {ECO:0000244|PDB:1X9D}.
FT   TURN        503    505       {ECO:0000244|PDB:1X9D}.
FT   STRAND      508    510       {ECO:0000244|PDB:1X9D}.
FT   STRAND      512    514       {ECO:0000244|PDB:1X9D}.
FT   STRAND      517    519       {ECO:0000244|PDB:1X9D}.
FT   STRAND      521    523       {ECO:0000244|PDB:1X9D}.
FT   HELIX       524    527       {ECO:0000244|PDB:1X9D}.
FT   HELIX       528    538       {ECO:0000244|PDB:1X9D}.
FT   HELIX       543    561       {ECO:0000244|PDB:1X9D}.
FT   STRAND      563    566       {ECO:0000244|PDB:1FO2}.
FT   STRAND      570    573       {ECO:0000244|PDB:1X9D}.
FT   STRAND      584    586       {ECO:0000244|PDB:1FO3}.
FT   HELIX       589    591       {ECO:0000244|PDB:1X9D}.
FT   HELIX       599    611       {ECO:0000244|PDB:1X9D}.
FT   HELIX       615    630       {ECO:0000244|PDB:1X9D}.
FT   HELIX       659    662       {ECO:0000244|PDB:1X9D}.
FT   HELIX       664    672       {ECO:0000244|PDB:1X9D}.
FT   TURN        676    679       {ECO:0000244|PDB:1FO3}.
FT   TURN        681    683       {ECO:0000244|PDB:1X9D}.
FT   STRAND      684    686       {ECO:0000244|PDB:1X9D}.
FT   STRAND      692    694       {ECO:0000244|PDB:1X9D}.
SQ   SEQUENCE   699 AA;  79580 MW;  B8BF3BE333D90261 CRC64;
     MAACEGRRSG ALGSSQSDFL TPPVGGAPWA VATTVVMYPP PPPPPHRDFI SVTLSFGENY
     DNSKSWRRRS CWRKWKQLSR LQRNMILFLL AFLLFCGLLF YINLADHWKA LAFRLEEEQK
     MRPEIAGLKP ANPPVLPAPQ KADTDPENLP EISSQKTQRH IQRGPPHLQI RPPSQDLKDG
     TQEEATKRQE APVDPRPEGD PQRTVISWRG AVIEPEQGTE LPSRRAEVPT KPPLPPARTQ
     GTPVHLNYRQ KGVIDVFLHA WKGYRKFAWG HDELKPVSRS FSEWFGLGLT LIDALDTMWI
     LGLRKEFEEA RKWVSKKLHF EKDVDVNLFE STIRILGGLL SAYHLSGDSL FLRKAEDFGN
     RLMPAFRTPS KIPYSDVNIG TGVAHPPRWT SDSTVAEVTS IQLEFRELSR LTGDKKFQEA
     VEKVTQHIHG LSGKKDGLVP MFINTHSGLF THLGVFTLGA RADSYYEYLL KQWIQGGKQE
     TQLLEDYVEA IEGVRTHLLR HSEPSKLTFV GELAHGRFSA KMDHLVCFLP GTLALGVYHG
     LPASHMELAQ ELMETCYQMN RQMETGLSPE IVHFNLYPQP GRRDVEVKPA DRHNLLRPET
     VESLFYLYRV TGDRKYQDWG WEILQSFSRF TRVPSGGYSS INNVQDPQKP EPRDKMESFF
     LGETLKYLFL LFSDDPNLLS LDAYVFNTEA HPLPIWTPA
//
